As antibody-drug conjugates aspire to advance to earlier-line treatments, harnessing innovation has never been more important to redefine the oncology standard of care and provide long-term benefit to patients.
Returning as the annual touchpoint for the global community, the 16th World ADC San Diego is THE week to fully immerse yourself in all things antibody-drug conjugate, spotlighting the cutting-edge innovation empowering the industry to develop differentiated ADCs that show clear advantages against standard-of-care therapies with clinically meaningful patient benefit.
With 7 streams of end-to-end content spanning discovery chemistry, discovery biology, preclinical, translational medicine, clinical lessons, process and analytical development, and manufacturing and supply chain: this is your one-stop bioconjugate shop to bring your team up to speed with ADC fundamentals, get answers to the problems hindering your ADC R&D, and identify emerging trends to ensure you stay ahead of the curve.
Providing unparalleled networking opportunities with 1,400+ attendees from start-ups, biotechs, large pharma and leading service providers, anybody who is anybody in the ADC field will unite under one roof to innovate, collaborate, and redefine the standard of oncology care.
